Oman Pharmaceutical Products

What Oman Pharmaceutical Products does

Oman Pharmaceutical Products Co. LLC (OPP) is a pharmaceutical manufacturer based in Seeb, Sultanate of Oman, established in 2001 and operating as a subsidiary of the diversified Al Bahja Group. The company manufactures and markets branded generic prescription pharmaceuticals and over-the-counter (OTC) consumer products, including its Hygienex OTC brand. OPP operates with a headcount of 101-250 employees and runs in-house functions spanning research and development, manufacturing, and quality assurance. Its corporate presence is bilingual (English and Arabic) and includes pharmacovigilance infrastructure.

Beyond finished product manufacturing, OPP operates a four-pillar global business platform: in-licensing of third-party pharmaceutical products and technologies, out-licensing of its own products to international markets, Contract Research and Manufacturing Services (CRAMS), and strategic alliances with other pharmaceutical companies. The company targets three customer segments: healthcare providers (via prescription drug channels), the prescription drug market, and the OTC consumer market (via retail channels). Distribution is described as global through licensing arrangements, though no specific country footprints or named customers are disclosed.

OPP's revenue mechanics span (1) direct sales of branded generics and OTC products, (2) royalty, milestone, and licensing income from in- and out-licensing arrangements, and (3) contract manufacturing and research fees from CRAMS engagements. Pricing is not publicly disclosed, no revenue figures are available, and no customer logos or concentration data have been published. No certifications, patents, trademarks, or regulatory filings are disclosed in the input data, and the company's AI/technology stack is limited to standard pharmaceutical manufacturing with no disclosed AI/ML capabilities.

Name

Oman Pharmaceutical Products

Legal name

Oman Pharmaceutical Products Co. LLC

Website

https://omanpharma.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

101–250 employees

Short description

Oman Pharmaceutical Products Co. LLC is an Oman-based pharmaceutical manufacturer and global marketer of branded generic prescription drugs and OTC products, including the Hygienex brand, operating under the Al Bahja Group with a four-pillar global business platform spanning licensing, CRAMS, and strategic alliances.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Prescription Pharmaceutical (Rx) Wholesale Distribution (CRAOAHAA)

Keywords

• Branded generics manufacturing
• Prescription pharmaceuticals
• Over-the-counter medicines
• Contract pharmaceutical manufacturing
• Pharmaceutical licensing services

Headquarters

HQ city

Muscat

HQ country

Oman

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Distribution channels1 record

Marketing channels1 record

Core offering

Oman Pharmaceutical Products Co. LLC (OPP) is a pharmaceutical manufacturer based in the Sultanate of Oman that manufactures and markets branded generics globally. The company produces prescription pharmaceuticals and OTC products including its Hygienex brand, and offers business development services such as In-Licensing, Out-Licensing, Contract Research and Manufacturing Services (CRAMS), and Strategic Alliances to serve domestic and international markets.

Product overview

Oman Pharmaceutical Products Co. LLC (OPP) is a pharmaceutical manufacturer based in the Sultanate of Oman. The company operates across two main product categories: Prescription Products (pharmaceuticals requiring a doctor's prescription) and OTC Products (over-the-counter medications including the Hygienex brand). Beyond manufacturing, OPP offers business development services including In-Licensing and Out-Licensing arrangements, Contract Research and Manufacturing Services (CRAMS), and Strategic Alliances. The company maintains global business presence serving international markets through various partnership models.

Differentiator

Problem solved

Functional benefit

Brands

• Hygienex: OTC brand referenced on the company website under the products section.

Products and services

• Prescription Products Pharmaceutical products available by prescription from healthcare providers, manufactured by OPP as part of its branded generics portfolio.
• OTC Products Over-the-counter pharmaceutical products available without prescription, marketed under OPP's OTC brands including Hygienex.
• Hygienex Hygienex is OPP's OTC brand of over-the-counter consumer health products.
• In-Licensing Services Service offering for in-licensing pharmaceutical products and technologies into OPP's portfolio for the Oman market and surrounding regions.
• Out-Licensing Services Service offering for licensing out OPP's pharmaceutical products to distribution partners in international markets.
• CRAMS (Contract Research and Manufacturing Services) Contract Research and Manufacturing Services (CRAMS) offered by OPP, providing pharmaceutical manufacturing capabilities to third parties on a contract basis.
• Strategic Alliance Partnerships Strategic alliances formed with pharmaceutical companies to support global pharmaceutical business expansion.

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core.

• In-Licensing PartnerscoreStrategic or Co-development PartnerCompany engages in in-licensing arrangements for pharmaceutical products and technologies.
• Out-Licensing PartnerscoreStrategic or Co-development PartnerCompany engages in out-licensing arrangements to distribute products in international markets.
• CRAMS PartnerscoreStrategic or Co-development PartnerContract Research and Manufacturing Services (CRAMS) partnerships for pharmaceutical manufacturing.
• Strategic Alliance PartnerscoreStrategic or Co-development PartnerStrategic alliances for global pharmaceutical business expansion.

Recent moves5 records

Expansion highlights4 records

Direct peers

• Tabuk Pharmaceuticals: Saudi pharma manufacturer focused on branded generics across MENA, with comparable in-licensing and manufacturing operations targeting similar regional healthcare providers.
• Julphar (Gulf Pharmaceutical Industries): UAE-based pharmaceutical manufacturer of branded generics with regional MENA presence and licensing operations, closely comparable to OPP's manufacturing-and-distribution model across similar therapeutic categories.
• Pharco Pharmaceuticals: Egypt-based pharmaceutical manufacturer producing branded generics for MENA and African markets, offering regional similarity and matching OPP's emerging-markets distribution focus.
• Jazeera Pharmaceutical Industries (JPI): Kuwaiti/Saudi pharmaceuticals manufacturer producing Rx and OTC generics across the Gulf, sharing OPP's regional positioning, manufacturing scale, and contract service approach.
• SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corp.): Saudi pharmaceutical manufacturer producing branded generics and OTC products for regional and export markets, mirroring OPP's GCC manufacturing footprint and product mix.

Broad incumbents

• Lupin Limited: Indian branded generics manufacturer with international footprint across regulated and emerging markets, offering comparable Rx/OTC branded generics product mix at larger scale.
• Cipla: India-based global generics powerhouse active in branded and complex generics across emerging markets, comparable in product mix and in-licensing orientation though at vastly greater scale.
• Dr. Reddy's Laboratories: Indian multinational generics manufacturer with strong presence in emerging markets and active in licensing partnerships, comparable business model to OPP but with global scale and branded formulations.
• Aurobindo Pharma: Large Indian generics manufacturer with global distribution and contract manufacturing operations through its CRAMS arm, overlapping with OPP's dual manufacturing-and-CRAMS business model.
• Hikma Pharmaceuticals: Major MENA-headquartered generics and injectables manufacturer with global distribution, operating a much broader portfolio that overlaps with OPP's branded generics and licensing approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/profile.php

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oman Pharmaceutical Products